Pfizer CEO Albert Bourla (Drew Angerer/Getty Images)
Pfizer predicts a $15B avalanche of cash from its Covid-19 vaccine in 2021 as the R&D team claims a big spike in the trial success rate
If anyone wants a lesson in the value of being first-in-class and best-in-class in the drug business, pick up a copy of Pfizer’s quarterly report …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
